Comparative Study of Antimicrobial Effectiveness

• ClinicalTrials.gov Identifier: NCT03817580
• Recruitment Status: Completed
• First Posted: January 25, 2019
• Results First Posted: October 22, 2021
• Last Update Posted: October 22, 2021
• Sponsor: Professional Disposables International, Inc.
• Information provided by (Responsible Party): Professional Disposables International, Inc.

Study Description

Brief Summary:

Comparative Study of Antimicrobial Effectiveness Evaluation of 26 ml Project X, 5.1ml Project X and Prevantics® Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West Conshohocken, PA, 2015,

Condition or disease	Intervention/treatment	Phase
Bacterial Microflora Reduction	Drug: Project X 26ml; Drug: Project X 5.1ml; Drug: Prevantics Maxi Swabstick	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 170 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Masking Description: Samples are blinded to the participant and technical team.
• Primary Purpose: Prevention
• Official Title: Comparative Study of Antimicrobial Effectiveness Evaluation of 26 ml Project X, 5.1 ml Project X and Prevantics® Maxi Swabstick Following ASTM E1173
• Actual Study Start Date: February 18, 2019
• Actual Primary Completion Date: June 4, 2019
• Actual Study Completion Date: June 4, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Project X 26ml; 3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.	Drug: Project X 26ml; Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Experimental: Project X 5.1ml; 3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.	Drug: Project X 5.1ml; Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Active Comparator: Prevantics Maxi Swabstick; 3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.	Drug: Prevantics Maxi Swabstick; Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Outcome Measures

Primary Outcome Measures :

1. Change in Bacterial Microflora on the Inguinal Area [ Time Frame: 30 seconds ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention
2. Change in Bacterial Microflora on the Inguinal Area [ Time Frame: 10 minutes ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention
3. Change in Bacterial Microflora on the Inguinal Area [ Time Frame: 6 hours ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention
4. Change in Bacterial Microflora on the Abdomen [ Time Frame: 30 seconds ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention
5. Change in Bacterial Microflora on the Abdomen [ Time Frame: 10 minutes ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention
6. Change in Bacterial Microflora on the Abdomen [ Time Frame: 6 hours ]
   Bacterial microflora (log10) will be measured via cup scrub method after administration of the intervention

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Male or female at least 18 years of age and of any race
2. In good general health
3. Read, understand and sign the Informed Consent Form (ICF)
4. If female of child-bearing potential, are willing to use an acceptable method of contraception to prevent pregnancy (i.e. oral contraceptive, intra-uterine device, diaphragm, condom, abstinence, bilateral tubal ligation, or are in a monogamous relationship with a partner who has had a vasectomy)
5. Female subjects of child-bearing potential, must have a negative Urine Pregnancy Test (UPT) on Treatment Day prior to any applications of the study products
6. Screening Day Baseline microbial counts are at least 3.11 colony forming units (CFU)/cm2 bilaterally from the skin of the abdomen, and 5.00 log10 colony forming units (CFU)/cm2 bilaterally from the skin of the groin (not applicable for Neutralization study)

Exclusion Criteria:

1. Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos, or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds, or sunbathing during the 14-day washout conditioning period and during the test period (7-day for Neutralization study)
2. Exposure of the test sites to strong detergents, solvents, or other irritants during the 14-day washout conditioning period and during the test period (7-day for Neutralization study)
3. Wear fabric softener, bug repellent or UV-treated clothing during the 14-day washout conditioning period and during the test period (7-day for Neutralization study)
4. Receive an irritation score of 1 (any redness, swelling, rash, or dryness present at any treatment area) for any individual skin condition prior to the Screening Day baseline or Treatment Day baseline sample collection or Neutralization study
5. Use of systemic or topical antibiotic medications, steroid medications (other than for hormonal contraception or post-menopausal reasons), or any other product known to affect the normal microbial flora of the skin during the 14-day washout conditioning period and during the test period (7-day for Neutralization study)
6. Known allergies or sensitivities to vinyl, latex (rubber), alcohols, metals, inks, or tape adhesives, or to common antibacterial agents found in soaps, lotions, or ointments, particularly isopropyl alcohol or chlorhexidine gluconate
7. A medical diagnosis of a physical condition, such as a current or recent severe illness, asthma, diabetes, hepatitis, an organ transplant, mitral valve prolapses, congenital heart disease, internal prostheses, or any immunocompromised conditions such as AIDS (or HIV positive)
8. Pregnancy, plans to become pregnant within the washout and test periods of the study, or nursing a child
9. Any tattoos or scars within 2" (5.08 cm) of the test sites
10. Dermatoses, cuts, lesions, active skin rashes, or breaks or other skin disorders within 6" on or around the test sites
11. A currently active skin disease or inflammatory skin condition (for example, contact dermatitis) anywhere on the body that, in the opinion of the Consulting Physician or PI, would compromise subject safety or study integrity
12. Showering, bathing, or swimming within the 72-hour period prior to sampling for baseline screening, Treatment Day, and throughout the test period (not applicable for Neutralization study)
13. Participation in another clinical study in the past 30 days or current participation in another clinical study at time of signing informed consent
14. Any medical condition or use of any medications that, in the opinion of the PI, should preclude participation
15. Unwillingness to fulfill the performance requirements of the study.

Contacts and Locations

Locations

Romania

Eurofins EVIC

Bucharest, Romania, 040256

Sponsors and Collaborators

Professional Disposables International, Inc.

Investigators

• Principal Investigator: Rozalia Olsavszky, MD; EUROFINS EVIC PRODUCT TESTING ROMANIA S.R.L

  Study Documents (Full-Text)

Documents provided by Professional Disposables International, Inc.:

Study Protocol and Statistical Analysis Plan  [PDF] January 14, 2019

More Information

• Responsible Party: Professional Disposables International, Inc.
• ClinicalTrials.gov Identifier: NCT03817580
• Other Study ID Numbers: ER18/282
• First Posted: January 25, 2019
• Results First Posted: October 22, 2021
• Last Update Posted: October 22, 2021
• Last Verified: October 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No